Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a price target of $15, down from $47. The firm has removed cibotercept for pulmonary arterial hypertension from the firm’s model following management’s voluntary decision to terminate the Phase 2 TROPOS study based on new cases of pericardial effusion observed from the 1.5mg/kg dose cohort, as well as KER-065 for obesity based on the revised strategy to prioritize neuromuscular indications, the analyst tells investors in a research note. Without the PAH program, the firm sees limited near-term catalysts from the partnered elritercept program that just entered Phase 3.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics downgraded to Neutral from Outperform at Wedbush
- Keros Therapeutics price target lowered to $15 from $40 at Piper Sandler
- Keros Therapeutics price target lowered to $41 from $44 at Scotiabank
- Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer
- Keros Therapeutics price target lowered to $32 from $33 at BofA